Citation: Leukemia. 32(1):131-138, 2018 01..Journal: Leukemia.Published: ; 2018ISSN: 0887-6924.Full author list: Lakshman A; Moustafa MA; Rajkumar SV; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK.UI/PMID: 28655925.Subject(s): Adult | Aged | Aged, 80 and over | Chromosome Aberrations | *Chromosomes, Human/ge [Genetics] | Female | Humans | In Situ Hybridization, Fluorescence/mt [Methods] | Male | Middle Aged | *Multiple Myeloma/ge [Genetics] | *Multiple Myeloma/pa [Pathology] | Neoplasm Staging/mt [Methods] | Prognosis | Translocation, Genetic/ge [Genetics] | Young AdultInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Internal MedicineActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1038/leu.2017.204 (Click here)Abbreviated citation: Leukemia. 32(1):131-138, 2018 01.Abstract: Translocation (11;14) on interphase FISH in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma (MM) based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 with no chromosomal translocation. The median progression-free survival (PFS) for the three groups were 23.0 (95% CI, 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months respectively [P<0.01]. The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months respectively [P<0.01]. Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months respectively [p P<0.01]. The above relationship held true in patients with age <65 years, ISS I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio [HR]: 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM is inferior to other standard risk patients.Leukemia accepted article preview online, 27 June 2017. doi:10.1038/leu.2017.204.